Stem Cell Therapeutics Corp. has announced that a patent by the U.S. Patent and Trademark Office -U.S. Patent 7,964,563 was granted.
The patent is entitled, "Oligodendrocyte Precursor Cell Proliferation Regulated By Prolactin." Claims granted in this Stem Cell Therapeutics Corp/ Patent focus protecting the therapeutic use of Prolactin for Multiple Sclerosis.
Dr. Allen Davidoff, SCT's Chief Scientific Officer, commented as follows: "We are very pleased by the granting of this patent, as it represents a cornerstone achievement in SCT's strategy to protect the use of prolactin for treating central nervous system disorders that involve white matter, and specifically for the treatment of Multiple Sclerosis.
This patent builds upon the strong basic scientific evidence that prolactin possesses the ability to stimulate endogenous stem cells to increase oligodendrocytes precursor cells in animals with central nervous system injuries and importantly increase the amount of myelin in white matter lesions. The anticipated MS clinical trial for the prolactin development program will substantially advance SCT's understanding how this important, novel neuro-regenerative therapy affects recovery in MS patients."